390 related articles for article (PubMed ID: 34986001)
1. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs.
McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE
J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001
[TBL] [Abstract][Full Text] [Related]
2. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.
Vietheer PT; Boo I; Gu J; McCaffrey K; Edwards S; Owczarek C; Hardy MP; Fabri L; Center RJ; Poumbourios P; Drummer HE
Hepatology; 2017 Apr; 65(4):1117-1131. PubMed ID: 27997681
[TBL] [Abstract][Full Text] [Related]
3. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
4. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
Pierce BG; Keck ZY; Wang R; Lau P; Garagusi K; Elkholy K; Toth EA; Urbanowicz RA; Guest JD; Agnihotri P; Kerzic MC; Marin A; Andrianov AK; Ball JK; Mariuzza RA; Fuerst TR; Foung SKH
J Virol; 2020 Oct; 94(22):. PubMed ID: 32878891
[TBL] [Abstract][Full Text] [Related]
6. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
J Virol; 2018 May; 92(9):. PubMed ID: 29467319
[TBL] [Abstract][Full Text] [Related]
7. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
[TBL] [Abstract][Full Text] [Related]
8. Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine.
Center RJ; Boo I; Phu L; McGregor J; Poumbourios P; Drummer HE
J Biol Chem; 2020 May; 295(21):7179-7192. PubMed ID: 32299914
[TBL] [Abstract][Full Text] [Related]
9. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies.
Tarr AW; Backx M; Hamed MR; Urbanowicz RA; McClure CP; Brown RJP; Ball JK
Antiviral Res; 2018 Dec; 160():25-37. PubMed ID: 30217650
[TBL] [Abstract][Full Text] [Related]
10. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.
Khera T; Behrendt P; Bankwitz D; Brown RJP; Todt D; Doepke M; Khan AG; Schulze K; Law J; Logan M; Hockman D; Wong JAJ; Dold L; Gonzalez-Motos V; Spengler U; Viejo-Borbolla A; Ströh LJ; Krey T; Tarr AW; Steinmann E; Manns MP; Klein F; Guzman CA; Marcotrigiano J; Houghton M; Pietschmann T
J Hepatol; 2019 Apr; 70(4):593-602. PubMed ID: 30439392
[TBL] [Abstract][Full Text] [Related]
11. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
Ruwona TB; Giang E; Nieusma T; Law M
J Virol; 2014 Sep; 88(18):10459-71. PubMed ID: 24965471
[TBL] [Abstract][Full Text] [Related]
12. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.
Flyak AI; Ruiz S; Colbert MD; Luong T; Crowe JE; Bailey JR; Bjorkman PJ
Cell Host Microbe; 2018 Nov; 24(5):703-716.e3. PubMed ID: 30439340
[TBL] [Abstract][Full Text] [Related]
13. Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes.
Wei S; Lei Y; Yang J; Wang X; Shu F; Wei X; Lin F; Li B; Cui Y; Zhang H; Wei S
Vaccine; 2018 Apr; 36(17):2273-2281. PubMed ID: 29576303
[TBL] [Abstract][Full Text] [Related]
14. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
[TBL] [Abstract][Full Text] [Related]
15. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.
Vasiliauskaite I; Owsianka A; England P; Khan AG; Cole S; Bankwitz D; Foung SKH; Pietschmann T; Marcotrigiano J; Rey FA; Patel AH; Krey T
mBio; 2017 May; 8(3):. PubMed ID: 28512091
[TBL] [Abstract][Full Text] [Related]
16. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.
Keck ZY; Xia J; Wang Y; Wang W; Krey T; Prentoe J; Carlsen T; Li AY; Patel AH; Lemon SM; Bukh J; Rey FA; Foung SK
PLoS Pathog; 2012; 8(4):e1002653. PubMed ID: 22511875
[TBL] [Abstract][Full Text] [Related]
17. Junctional and somatic hypermutation-induced CX
Yi C; Xia J; He L; Ling Z; Wang X; Yan Y; Wang J; Zhao X; Fan W; Sun X; Zhang R; Ye S; Zhang R; Xu Y; Ma L; Zhang Y; Zhou H; Huang Z; Niu J; Long G; Lu J; Zhong J; Sun B
Cell Mol Immunol; 2021 Mar; 18(3):675-685. PubMed ID: 32235917
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region.
Alhammad Y; Gu J; Boo I; Harrison D; McCaffrey K; Vietheer PT; Edwards S; Quinn C; Coulibaly F; Poumbourios P; Drummer HE
J Virol; 2015 Dec; 89(24):12245-61. PubMed ID: 26378182
[TBL] [Abstract][Full Text] [Related]
19. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
[TBL] [Abstract][Full Text] [Related]
20. Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.
Urbanowicz RA; Wang R; Schiel JE; Keck ZY; Kerzic MC; Lau P; Rangarajan S; Garagusi KJ; Tan L; Guest JD; Ball JK; Pierce BG; Mariuzza RA; Foung SKH; Fuerst TR
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]